title: The association of XPG and MMS19L polymorphisms response to chemotherapy in osteosarcoma.
abstract: OBJECTIVE
  To assess the role of XPG, XPC, CCNH and MMS19L polymorphisms response to chemotherapy in osteosarcoma, and the clinical outcome of osteosarcoma.
  
  
  METHODS
  One hundred and sixty eight osteosarcoma patients who were histologically confirmed were enrolled in our study between January 2007 and March 2009. Genotyping of XPG, XPC, CCNH and MMS19L was performed in a 384-well plate format on the MassARRAY® platform.
  
  
  RESULTS
  Individuals with rs2296147 TT genotype showed a better response as compared with CC genotype, with the OR (95% CI) of 3.89(1.49-10.95). Those carrying rs29001322 TT genotype presented better response to chemotherapy, and the OR (95% CI) was as high as 12.25(2.63-121.84). Patients carrying TT genotype of XPG rs2296147 and MMS19L rs29001322 showed a significantly longer overall survival than CC genotype, they had 0.37 and 0.31-fold risk of death when compared with wide-type of this gene.
  
  
  CONCLUSIONS
  XPG rs2296147 and MMS19L rs29001322 are correlated with response to chemotherapy and prognosis of osteosarcoma. Our findings would provide important evidence for prognostic and therapeutic implications in osteosarcoma.
authors.affiliation: Yi-lei Zhao, Department of Orthopedic Surgery, the First Affiliated Hospital, Xinxiang Medical College, Xinxiang, China.
authors.forename: Yi-Lei
authors.initials: YL
authors.lastname: Zhao
authors.affiliation: Li-bin Yang, Department of Orthopedic Surgery, the First Affiliated Hospital, Xinxiang Medical College, Xinxiang, China.
authors.forename: Li-Bin
authors.initials: LB
authors.lastname: Yang
authors.affiliation: Xiao-lin Geng, Department of Orthopedic Surgery, the First Affiliated Hospital, Xinxiang Medical College, Xinxiang, China.
authors.forename: Xiao-Lin
authors.initials: XL
authors.lastname: Geng
authors.affiliation: Qing-lan Zhou, Department of Orthopedic Surgery, the First Affiliated Hospital, Xinxiang Medical College, Xinxiang, China.
authors.forename: Qing-Lan
authors.initials: QL
authors.lastname: Zhou
authors.affiliation: Hua Qin, Department of Orthopedic Surgery, the First Affiliated Hospital, Xinxiang Medical College, Xinxiang, China.
authors.forename: Hua
authors.initials: H
authors.lastname: Qin
authors.affiliation: Lin Yang, Department of Orthopedic Surgery, the First Affiliated Hospital, Xinxiang Medical College, Xinxiang, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Yang
authors.affiliation: Yu-zhen Dong, Department of Orthopedic Surgery, the First Affiliated Hospital, Xinxiang Medical College, Xinxiang, China.
authors.forename: Yu-Zhen
authors.initials: YZ
authors.lastname: Dong
authors.affiliation: Jin-Jie Zhong, Department of Histology & Embryology, Xinjiang Medical University, 393 Xinyi Road, Urumqi, China.
authors.forename: Jin-Jie
authors.initials: JJ
authors.lastname: Zhong
keywords: Clinical outcome; MMS19L; Osteosarcoma; XPG